NASDAQ:MNOV

MediciNova (MNOV) Stock Price, News & Analysis

MediciNova logo
$1.33 -0.01 (-0.75%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 +0.00 (+0.38%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About MediciNova Stock (NASDAQ:MNOV)

Advanced

Key Stats

Today's Range
$1.26
▼
$1.41
50-Day Range
$1.33
▼
$3.45
52-Week Range
$1.22
▼
$3.90
Volume
115,567 shs
Average Volume
49,955 shs
Market Capitalization
$68.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75
Consensus Rating
Moderate Buy

Company Overview

MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

AI Generated. May Contain Errors.

MediciNova Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

MNOV MarketRank™: 
2.9483015293 of 5 stars

MediciNova scored higher than 59% of companies evaluated by MarketBeat, and ranked 753rd out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MediciNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    MediciNova has a consensus price target of $7.75, representing about 482.7% upside from its current price of $1.33.

  • Amount of Analyst Coverage

    MediciNova has only been the subject of 3 research reports in the past 90 days.

  • Read more about MediciNova's stock forecast and price target.
  • Earnings Growth

    Earnings for MediciNova are expected to decrease in the coming year, from ($0.25) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MediciNova is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MediciNova is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MediciNova has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.67% of the float of MediciNova has been sold short.
  • Short Interest Ratio / Days to Cover

    MediciNova has a short interest ratio ("days to cover") of 5.44.
  • Change versus previous month

    Short interest in MediciNova has recently decreased by 2.44%, indicating that investor sentiment is improving.
  • Dividend Yield

    MediciNova does not currently pay a dividend.

  • Dividend Growth

    MediciNova does not have a long track record of dividend growth.

  • News Sentiment

    MediciNova has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for MediciNova this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, MediciNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,728,000.00 in company stock.

  • Percentage Held by Insiders

    14.00% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    9.90% of the stock of MediciNova is held by institutions.

  • Read more about MediciNova's insider trading history.
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MNOV Stock News Headlines

Medicinova Inc
MediciNova to Participate in the Maxim Growth Summit
The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More Headlines

MNOV Stock Analysis - Frequently Asked Questions

MediciNova's stock was trading at $1.31 at the beginning of the year. Since then, MNOV stock has increased by 1.5% and is now trading at $1.33.

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.00. The biopharmaceutical company had revenue of $138.56 thousand for the quarter, compared to the consensus estimate of $50 thousand. MediciNova had a negative net margin of 1,126.60% and a negative trailing twelve-month return on equity of 26.47%.

MediciNova's top institutional investors include Goldman Sachs Group Inc. (1.25%), State Street Corp (0.39%), Empowered Funds LLC (0.10%) and Jump Financial LLC (0.04%).
View institutional ownership trends
.

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include NVIDIA (NVDA), Nokia (NOK), Ideanomics (IDEX), SNDL (SNDL), Tonix Pharmaceuticals (TNXP), Ford Motor (F) and GE Aerospace (GE).

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MNOV
CIK
1226616
Employees
6
Year Founded
2000

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
+482.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12 million
Net Margins
-1,126.60%
Pretax Margin
-1,126.07%
Return on Equity
-26.47%
Return on Assets
-24.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.75
Quick Ratio
8.75

Sales & Book Value

Annual Sales
$410 thousand
Price / Sales
166.19
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.80 per share
Price / Book
1.66

Miscellaneous

Outstanding Shares
51,230,000
Free Float
44,060,000
Market Cap
$68.14 million
Optionable
Optionable
Beta
0.71

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:MNOV) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners